Oxaliplatin (Eloxatin)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Platinum analog, alkylating-like, which produces interstrand and intrastrand DNA crosslinks that inhibit DNA replication and transcription, causing non-cell cycle specific cytotoxicity and death.[1][2][3]
Route: IV
Extravasation: irritant (usually), vesicant (rare)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Colon cancer

  • 11/4/2004: New indication: "used in combination with infusional 5-FU/ LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.

Colorectal cancer

Also known as

  • Code names: JM-83, RP-54780, SR-96669
  • Brand names: Coxatin, Curaplat, Cure-X, Dacotin, Dacplat, Eloplat, Eloxatin, Eloxatine, Oplatin, OxaLitin, Oxiplat, Oxitan, Oxzucia, Sibatin, Xaloplat, Xylotin, X-Plat, Zildox